BCM
CLVS

Bayesian Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Bayesian Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-22,100
Closed -$106K – 740
2020
Q4 		$106K Buy
22,100
+1,400
+7% +$7.08K 0.03% 415
2020
Q3 		$121K Sell
20,700
-5,300
-20% -$31.7K 0.03% 470
2020
Q2 		$176K Sell
26,000
-68,043
-72% -$515K 0.04% 448
2020
Q1 		$598K Buy
+94,043
New +$754K 0.13% 241

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bayesian Capital Management's CLVS Position: Q1 2021 in Review

Bayesian Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q1 2021, closing a stake of 22,100 shares — an estimated $106K sold.

Bayesian Capital Management first reported a position in CLVS in Q1 2020 and held it in 4 quarters. The position peaked at $598K in Q1 2020. 165 funds tracked by Wall St. Rank hold CLVS as of Q1 2021.

  • Bayesian Capital Management reported no remaining Clovis Oncology, Inc. position as of Q1 2021 after selling out during the quarter.
  • Bayesian Capital Management sold 22,100 Clovis Oncology, Inc. shares in Q1 2021, an estimated $106K.
  • Bayesian Capital Management first reported a position in Clovis Oncology, Inc. in Q1 2020 and held it in 4 quarters.
  • Bayesian Capital Management's Clovis Oncology, Inc. position peaked at $598K in Q1 2020.
  • 165 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2021.

Based on Bayesian Capital Management's 13F filing for Q1 2021, filed 14 May 2021.